Jump to content

Faralimomab

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Entranced98 (talk | contribs) at 04:23, 3 April 2023 (Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Faralimomab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetInterferon receptor
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Faralimomab is a mouse monoclonal antibody and an immunomodulator.[1][2]

References

[edit]
  1. ^ "WHO Drug Information" (PDF). Archived from the original (PDF) on 2011-06-04. Retrieved 2009-09-24.
  2. ^ Pelletier JP, Mukhtar F (2020). "Chapter 16 - Passive Monoclonal and Polyclonal Antibody Therapies". In Maitta RW (ed.). Immunologic Concepts in Transfusion Medicine. Philadelphia: Elsevier. p. 286. doi:10.1016/B978-0-323-67509-3.00016-0. ISBN 978-0-323-67510-9. S2CID 213508934.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Faralimomab&oldid=1147939060"